Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $51,390 | $9,057 | $6,094 | $5,762 |
| % Growth | 467.4% | 48.6% | 5.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $51,390 | $9,057 | $6,094 | $5,762 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $13,642 | $13,152 | $12,049 | $10,759 |
| G&A Expenses | $7,379 | $3,982 | $3,536 | $3,493 |
| SG&A Expenses | $7,497 | $4,062 | $3,617 | $3,531 |
| Sales & Mktg Exp. | $118 | $80 | $81 | $38 |
| Other Operating Expenses | $4,078 | $3,472 | $0 | $0 |
| Operating Expenses | $25,217 | $20,686 | $19,675 | $17,782 |
| Operating Income | $26,173 | -$11,629 | -$13,302 | -$12,357 |
| % Margin | 50.9% | -128.4% | -218.3% | -214.5% |
| Other Income/Exp. Net | -$4,779 | -$4,571 | -$4,170 | -$2,527 |
| Pre-Tax Income | $21,394 | -$16,200 | -$17,472 | -$14,884 |
| Tax Expense | $5,551 | $24 | $21 | $17 |
| Net Income | $15,843 | -$16,224 | -$17,493 | -$14,901 |
| % Margin | 30.8% | -179.1% | -287.1% | -258.6% |
| EPS | 0.85 | -0.91 | -0.98 | -0.84 |
| % Growth | 193.4% | 7.1% | -16.7% | – |
| EPS Diluted | 0.85 | -0.91 | -0.98 | -0.84 |
| Weighted Avg Shares Out | 18,563 | 17,845 | 17,845 | 17,845 |
| Weighted Avg Shares Out Dil | 18,563 | 17,845 | 17,845 | 17,845 |
| Supplemental Information | – | – | – | – |
| Interest Income | $138 | $179 | $56 | $2,864 |
| Interest Expense | $4,353 | $4,168 | $4,363 | $2,918 |
| Depreciation & Amortization | $192 | $201 | $202 | $209 |
| EBITDA | $25,939 | -$11,831 | -$13,323 | -$11,757 |
| % Margin | 50.5% | -130.6% | -218.6% | -204% |